ArticleMycoses2026
Histoplasma Urinary Antigen for the Diagnosis Histoplasmosis in Non-HIV Individuals.
Article in Mycoses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHistoplasmosis is an endemic mycosis in the Americas. While urinary Histoplasma antigen enzyme immunoassay testing (HAET) has been validated mainly in HIV-infected patients with disseminated disease, its performance in HIV-negative populations with heterogeneous clinical presentations is unclear.
objectivesTo describe the performance of urinary HAET for the diagnosis of histoplasmosis in a cohort of Brazilian HIV-negative patients. MATERIAL AND
methodsWe conducted a retrospective study at Einstein Hospital Israelita (Brazil) including HIV-negative patients whose urine samples were analysed by Histoplasma antigen enzyme immunoassay test (HAET) from January 2022 to October 2025. Factors associated with positive urinary HAET were analysed using univariable and multivariable models. Among 346 patients, histoplasmosis was diagnosed in 43 (12%); 16 (37%) were immunocompromised and 14 (33%) had disseminated disease. Urinary HAET was positive in eight patients (19%), with antigen levels from 0.3 to > 15 ng/mL. Sensitivity and specificity were 19% and 100%, respectively; positive and negative predictive values were 100% and 90%. Sensitivity increased to 45% in immunocompromised patients with multiorgan involvement, and immunocompromised status independently predicted HAET positivity (p = 0.008). In HIV-negative patients, HAET demonstrates excellent specificity but low sensitivity, performing best in immunocompromised individuals with disseminated histoplasmosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.